HowardKSurksMD

Cardiology • Boston, MA

Cardiovascular research at Merck Research Laboratories

Join to view full profile

Dr. Surks is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Surks' full profile

Already have an account?

Office
750 Washington St
Box 80
Boston, MA 02111
Phone+1 617-636-0619

Education & Training

Tufts Medical CenterFellowship, Cardiovascular Disease, 1994 - 1996
Tufts Medical CenterResidency, Internal Medicine, 1989 - 1992
Albert Einstein College of MedicineClass of 1989

Certifications & Licensure

NJ State Medical License 2012 - 2024

Publications & Presentations

PubMed

4 citations
First-in-human study with SAR445088: A novel selective classical complement pathway inhibitor.
Timothy Chow, Pirouz Shamszad, Christopher Vinnard, Esther Yoon, Julia Belinski
Clinical and Translational Science. 2023-04-01
95 citations
Heart Failure With Preserved Ejection Fraction Expert Panel Report: Current Controversies and Implications for Clinical Trials
Kishan S. Parikh, Kavita Sharma, Mona Fiuzat, Howard K. Surks, Jyothis T. George
JACC. Heart Failure. 2018-08-01
13 citations
Safety of Insulin Lispro and a Biosimilar Insulin Lispro When Administered Through an Insulin Pump.
James Thrasher, Howard Surks, Irene Nowotny, Suzanne Pierre, Baerbel Rotthaeuser
Journal of Diabetes Science and Technology. 2018-01-23

Journal Articles

Heart Failure with Preserved Ejection Fraction Expert Panel Report
Kishan S Parikh, Howard K Surks, Sanjiv J Shah, Marvin A Konstam, Margaret M Redfield, Robert M Califf, Kavita Sharma, Narimon Honarpour, Gregory D Lewis, Scott D Solo..., ScienceDirect

Press Mentions

Immune Regulation Makes Peter Greenleaf Chairman and Assembles a Quintet of New Execs; Bob Coughlin Moves on from MassBio to JLLDecember 18th, 2020
Cardurion Pharmaceuticals Presents Positive Clinical Results from CARDINAL‑HF Phase 2a Clinical Trial of PDE9 Inhibitor in Patients with Heart FailureMay 14th, 2024

Grant Support

Myosin Phosphatase Regulation In Vascular Smooth MuscleNational Heart, Lung, And Blood Institute2004–2008
CGMP Dependent Protein Kinase In Vascular BiologyNational Heart, Lung, And Blood Institute1999–2003
Cbmp Gated Channels In Cardiovascular PhysiologyNational Heart, Lung, And Blood Institute1995–1998